Lycera’s novel approach to developing selective oral immunomodulators positions the company to have a significant impact in treating autoimmune diseases with high unmet medical need. Lycera has brought together leaders and scientists who represent the best of their individual fields to build a team with the unique credentials to transform the direction of drug development and treatment for autoimmune diseases.
Lycera is focused on developing oral small-molecule medicines to treat autoimmune diseases. Both the bioenergetics and Th17 pathways have been validated in preclinical/clinical studies. We believe that drugs developed from these platforms will have the potential for first-in-class oral efficacy without the safety and tolerability issues, or the burdensome injections associated with today’s biologic therapies.